

AHCCCS MEDICAL POLICY MANUAL

310-V - ATTACHMENT A - INFORMED CONSENT/ASSENT FOR **PSYCHOTROPIC MEDICATION TREATMENT**

I have discussed the following information with my Behavioral Health Medical Practitioner (BHMP) or other prescribing clinician for each medication listed below:

- The <u>diagnosis</u> and <u>target symptoms</u> for the medication recommended,
 The <u>possible benefits/intended outcome</u> of the treatment, and as applicable, all available procedures involved in the proposed treatment,
- The possible risks and side effects, including risks of medication to pregnant women and women who are breast feeding,
- The possible alternatives,
- The possible results of not taking the recommended medication,
- The possibility that my medication dose may need to be adjusted over time, in consultation with my behavioral health medical practitioner,
- My right to actively participate in my treatment by discussing medication concerns or questions with my behavioral health medical practitioner,
- My right to withdraw voluntary consent for medication at any time (unless the use of medications in my treatment is required in a court order or in a special treatment plan),
- For Members under 18 years of age, the Food and Drug Administration (FDA) status of the medication and the level of evidence supporting the recommended medication, and,
- For Members under 18 years of age, the youth is encouraged to assent or agree to the medication, but the youth's Health Care Decision Maker (HCDM) has the final say in consent for the use of medication unless the youth is emancipated.

I UNDERSTAND THE MEDICATION INFORMATION THAT HAS BEEN PROVIDED TO ME. BY SIGNING BELOW, I AGREE TO THE USE OF EACH MEDICATION.

	HOW WAS MEDICATION INFORMATION DISCUSSED?				
	☐ In-Person	☐ Over Telephone	□Via Telemedicine	☐ Previously*	
MEDICATION					
		BHMP/ or other			
		Prescribing Clinician's			
	Member's Initials:		_ Initials:		
	Date:		Date:		
	HCDM Initials**	Date:			
TARGET SYMPTOMS TO BE ADDRESSED***					
	HOW WAS MEDICATION INFORMATION DISCUSSED?				
	☐ In-Person	☐ Over Telephone	□ Via Telemedicine	☐ Previously*	
MEDICATION					
		BHMP/ or other			
	4				
MEDICATION	Member's Initials:		Prescribing Clinician's		
MEDICATION	Member's Initials:		Prescribing Clinician's Initials:		
MEDICATION	Member's Initials: Date:		<u> </u>		
MEDICATION			Initials:		
MEDICATION	Date:		Initials: Date:		



AHCCCS MEDICAL POLICY MANUAL

310-V - ATTACHMENT A - INFORMED CONSENT/ASSENT FOR PSYCHOTROPIC MEDICATION TREATMENT

MEMBER'S PRINTED NAME	MEMBER'S SIGNATURE	MEMBER'S INITIALS
HCDM's PRINTED NAME	HCDM's SIGNATURE	HCDM's INITIALS
BHMP OR OTHER PRESCRIBING CLINICIAN'S PRINTED NAME	BHMP OR OTHER PRESCRIBING CLINICIAN'S SIGNATURE	BHMP OR OTHER PRESCRIBING CLINICIAN'S INITIALS

- * "Previously Discussed" indicates the medication has been discussed in a previous setting (Hospital, another clinic, etc.) or by another BHMP and you are verifying that the person continues to consent to treatment with this medication.
- ** Ensure the informed consent form with original member's signature is in patient's file. If consent is obtained by telephone or through tele-medicine, individual may initial and date at the next face-to-face visit.
- *** Target Symptoms refer to specific symptoms associated with a diagnosis, such as tearfulness, hallucinations, insomnia.

List the target symptoms rather than the underlying diagnosis.